Lundbeck's Dunsire has something to cheer as Rexulti combo shows promise in PTSD
With generics eating into sales of three key drugs and a recent key setback in schizophrenia, new Lundbeck CEO Deborah Dunsire can finally enjoy a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
